This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
THOUSAND OAKS, Calif.,
Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta
® (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer. FOLFOX and FOLFIRI are two of the most commonly used chemotherapy regimens for colorectal cancer.
The study met its primary endpoint, with Neulasta significantly reducing the incidence of febrile neutropenia. Febrile neutropenia is a low white blood cell count accompanied by a fever.
1 In the study, the incidence of grade 3 or 4 febrile neutropenia in patients receiving Neulasta across the first four cycles of chemotherapy was 2.4 percent compared to 5.7 percent in the placebo group (OR=0.41,
p=0.014). A similar incidence of grade 3 or higher adverse events was seen in both arms of the trial (28 percent placebo; 27 percent Neulasta).
"This analysis showed that PAVES met its primary endpoint, with Neulasta significantly reducing the incidence of febrile neutropenia in patients with colorectal cancer," said
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "In addition to providing new data on Neulasta, we believe PAVES will provide valuable information to the oncology community on commonly-used chemotherapy regimens."
Full results will be presented on
Saturday, Jan. 26 during the 2013 Gastrointestinal Cancers Symposium, General Poster Session C (C1) by
Tamas Pinter, M.D., the PAVES principal investigator, Aladar Korhaz Hospital, Onkoradiologiai Osztaly, Gyor,
Hungary (Late Breaking Abstract No. 445).
Follow-up results of PAVES looking at additional endpoints, including mature data on overall survival, overall response rate, time to progression and progression-free survival, will be presented at a future date.